3-Deazaneplanocin A
3-Deazaneplanocin A
Names
Preferred IUPAC name
(1S ,2R ,5R )-5-(6-Amino-9H -purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
Identifiers
ChemSpider
ECHA InfoCard
100.224.238
UNII
InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
Key: OMKHWTRUYNAGFG-IEBDPFPHSA-N
InChI=1/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
Key: OMKHWTRUYNAGFG-IEBDPFPHBD
n3ccc1c(ncn1[C@@H]2/C=C(/CO)[C@@H](O)[C@H]2O)c3N
Properties
C12 H14 N4 O3
Molar mass
262.265
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
3-Deazaneplanocin A (DZNep , C-c3Ado ) is a drug which acts as both a S -adenosylhomocysteine synthesis inhibitor and also a histone methyltransferase EZH2 inhibitor. Studies have shown that it has effects in vitro against a variety of different tumor cell lines .[ 1] [ 2] [ 3] [ 4] [ 5]
In studies on mice, the drug was also found to be effective for the treatment of Ebola virus disease ,[ 6] apparently interfering with the Ebola viruses ability to block interferon production, thus restoring the ability of immune system to rid the body of ebolavirus.[ 7] [ 8]
References
^ Glazer, R.I.; Knode, M.C.; Tseng, C.K.; Haines, D.R.; Marquez, V.E. (1986). "3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells" . Biochemical Pharmacology . 35 (24). Elsevier: 4523–7. doi :10.1016/0006-2952(86)90774-4 . PMID 3790170 .
^ Fiskus, W.; Wang, Y.; Sreekumar, A.; Buckley, K. M.; Shi, H.; Jillella, A.; Ustun, C.; Rao, R.; Fernandez, P.; Chen, J.; Balusu, R.; Koul, S.; Atadja, P.; Marquez, V. E.; Bhalla, K. N. (2009). "Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells" . Blood . 114 (13): 2733–2743. doi :10.1182/blood-2009-03-213496 . PMC 2756128 . PMID 19638619 .
^ Kikuchi, Junko; Takashina, Taichi; Kinoshita, Ichiro; Kikuchi, Eiki; Shimizu, Yasushi; Sakakibara-Konishi, Jun; Oizumi, Satoshi; Marquez, Victor E.; Nishimura, Masaharu; Dosaka-Akita, Hirotoshi (2012). "Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells" . Lung Cancer . 78 (2): 138–143. doi :10.1016/j.lungcan.2012.08.003 . PMC 3472089 . PMID 22925699 .
^ Liang, Shen (2013). "3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells". Asian Pacific Journal of Cancer Prevention . 14 (5). ISSN 1513-7368 .
^ Fujiwara, T.; Saitoh, H.; Inoue, A.; Kobayashi, M.; Okitsu, Y.; Katsuoka, Y.; Fukuhara, N.; Onishi, Y.; Ishizawa, K.; Ichinohasama, R.; Harigae, H. (2014). "3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation" . Journal of Biological Chemistry . 289 (12): 8121–8134. doi :10.1074/jbc.M114.548651 . PMC 3961643 . PMID 24492606 .
^ Huggins, J.; Zhang, Z. X.; Bray, M. (1999). "Antiviral Drug Therapy of Filovirus Infections: S-Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus in Vitro and in a Lethal Mouse Model" . The Journal of Infectious Diseases . 179 : S240–7. doi :10.1086/514316 . PMID 9988190 .
^ Bray, M; Raymond, J. L.; Geisbert, T; Baker, R. O. (2002). "3-deazaneplanocin a induces massively increased interferon-alpha production in Ebola virus-infected mice" . Antiviral Research . 55 (1): 151–9. doi :10.1016/s0166-3542(02)00018-9 . PMID 12076759 .
^ Shuchman, M (2014). "Could interferon help treat Ebola?" . Canadian Medical Association Journal . 186 (16): 1204. doi :10.1503/cmaj.109-4906 . PMC 4216250 . PMID 25246419 .